MMV's key achievements over the last 20 years


Malaria killed over 1 million people, hitting the poorest in sub-Saharan Africa the hardest

Resistance to chloroquine, key medicine used to control malaria, had spread globally and the drug pipeline was virtually empty

MMV launched to develop new antimalarials for vulnerable populations


First industrial and academic organizations become part of the MMV network: GSK, University of Bristol, London School of Hygiene & Tropical Medicine, SmithKline Beecham, University of California, Roche, University of Nebraska and Swiss TPH


MMV announces core management team


Agreement signed with Shin Poong Pharma and WHO-TDR to develop an artemisinin-based combination therapy (ACT) containing pyronaridine and artesunate (Pyramax®)


Agreement signed with Novartis to develop a child-friendly ACT containing artemether and lumefantrine (Coartem® Dispersible)


Agreement signed with Alfasigma S.p.A, Oxford University and Holley Cotec to develop an ACT containing dihydroartemisinin and piperaquine (Eurartesim®)


First patient enrolled in Pyramax® trial at the Hospital for Tropical Diseases at Mahidol University in Bangkok


After a successful stakeholder review of its 6 years, MMV becomes a “3D” organization, adding “delivery” to its “discovery and development” activities


Major phase III studies completed for Eurartesim® and Pyramax® involving more than 6,000 patients

Bill & Melinda Gates Foundation calls for new global commitment to malaria eradication


First medicine: 2 years earlier than promised: Coartem®Dispersible, developed with partner Novartis, registered by SwissMedic, the first child-friendly ACT approved by a stringent regulatory authority

The “Consortium for ACT Private Sector Subsidy” (CAPSS) pilot launched in Uganda to demonstrate impact on access from subsidizing ACT pricing in rural private sector

MMV announces collaboration with GSK for development of tafenoquine for radical cure of P. vivax malaria


MMV, Drugs for Neglected Diseases initiative (DNDi) and Sanofi launch largest post-approval antimalarial safety cohort event monitoring study of artesunate + amodiaquine (ASAQ Winthrop®) involving 15,000+ patients in Côte d’Ivoire

MMV celebrates its 10th anniversary




Fourth medicine: Shin Poong Pharma’s Pyramax® for acute uncomplicated P. falciparum and P. vivax malaria receives a positive scientific opinion from EMA through Article 58

First molecules with potential for chemoprotection (KAF156 with Novartis and DSM265 with NIH and Takeda) enter clinical development

Eurartesim® deployed in Cambodia to help contain ACT drug resistance

Controlled human malaria infection model comes on stream at QIMR Berghofer in Australia to accelerate drug development: allows drug candidates to be tested in healthy individuals infected with malaria in carefully controlled conditions


Over 230 copies of the Malaria Box delivered to research groups globally

MMV now has 50 staff members and a global network of over 375 partners

Global malaria mortality down by 47% from 2000




Agreement signed with S Kant HEALTHCARE Ltd. to develop a second dispersible, taste-masked formulation of SPAQ for SMC

Pyramax® granules added to WHO’s list of prequalified medicines

UN Sustainable Development Goals launched



Tenth medicine: Strides Shasun’s artesunate rectal capsules receive WHO prequalification

Eleventh medicine: Tafenoquine for radical cure of P. vivax malaria is approved by the US FDA and the Australian TGA

Twelfth medicine: Second manufacturer of injectable artesunate secured – Ipca receives WHO prequalification in December for Larinate® 60

319 Pathogen Boxes shipped to scientists around the world free of charge

Fosun Pharma estimates over 120 million vials of Artesun® delivered since 2010

Ten compounds in MMV’s clinical development portfolio, including potential medicines for children, pregnant women and people suffering from drug-resistant malaria

405,000 deaths from malaria, less than half as many as in 1999


MMV launches Pandemic Response Box in partnership with DNDi to accelerate the discovery of new treatments for pandemic diseases

Thirteenth medicine: S Kant HEALTHCARE Ltd., second manufacturer of SPAQ for SMC, receives Global Fund expert review panel positive opinion, allowing for procurement by malaria-endemic countries with donor funds for one year while prequalification is ongoing

390 million treatments of Novartis’ Coartem® Dispersible delivered to over 50 countries since launch

Over 2.2 million lives saved by MMV-supported medicines

Over 100 staff on the MMV team

MMV celebrates its 20th anniversary